- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mendus AB (IMMUN)
The Mendus AB share price today is 6.850, view ST IMMUN stock exchange data. Track the latest Mendus AB share price with real-time updates on IMMUN stock performance including market cap, day range, 52-week range and dividend yield. Access IMMUN charts, earnings dates and analyst estimates to support your investment decisions.
Stockholm
Currency in SEK
6.850
+0.150(+2.24%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.650
7.190
52 wk Range
3.860
9.370
IMMUN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.6507.190
52 wk Range
3.8609.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMMUN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.000
Upside
+381.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.000
(+381.75% Upside)
Mendus AB Earnings Call Summary for Q2/2026
- Mendus reduced Q2 operating costs 14.9% to SEK 20.5M from SEK 24.1M, extending cash runway through Q1 2027 with SEK 59.9M on hand.
- Company reported 13 of 20 patients still alive in ADVANCE II AML study, advancing multiple trials including CADENCE, DIVA, and VITAL-CML programs.
- Shares rose 2.38% to $6.87 in pre-market trading, positioned mid-range between 52-week low of $3.86 and high of $9.37.
- Management expects steady clinical readouts over 6-12 months: DIVA trial start Q3 2026, VITAL-CML data H2 2026, full readouts Q3 2027.
- Additional financing will be required post-Q1 2027 to support pipeline expansion, including potential pediatric AML program and CADENCE scale-up.
Last Updated: 20-08-2026, 06:28 pm
Read Full TranscriptEarnings
Latest Release
20-08-2026
EPS / Forecast
-0.45 / --
Revenue / Forecast
-- / --
Compare IMMUN to Peers and Sector
Metrics to compare | IMMUN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMMUNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −2.0x | −0.3x | |
PEG Ratio | −0.25 | −0.35 | 0.00 | |
Price/Book | 0.8x | 10.4x | 2.6x | |
Price / LTM Sales | - | 132.6x | 3.1x | |
Upside (Analyst Target) | 381.8% | 0.0% | 47.6% | |
Fair Value Upside | Unlock | 39.9% | 5.6% | Unlock |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Mendus AB (IMMUN) Share Price Today?
The Mendus AB share price today is 6.850.
What is the current Mendus AB (IMMUN) share price and day range?
As of 22-08-2026, the Mendus AB share price is 6.850, with a previous close of 6.700. The share price has ranged from 6.650 to 7.190 today, while the 52-week range spans from 3.860 to 9.370.
What Is the Mendus AB Market Cap?
As of today, Mendus AB market cap is 426.990M.
What Is the Mendus AB (IMMUN) Share Price Target?
The average 12-month share price target for Mendus AB is 33.000, with a high estimate of 50 and a low estimate of 16. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +381.75% Upside potential.
What Is Mendus AB's Earnings Per Share (TTM)?
The Mendus AB EPS (TTM) is -1.766.
When Is the Next Mendus AB Earnings Date?
Mendus AB will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is IMMUN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Mendus AB Trade On?
Mendus AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Mendus AB?
The stock symbol for Mendus AB is "IMMUN."
How Many Times Has Mendus AB Stock Split?
Mendus AB has split 4 times.
How Many Employees Does Mendus AB Have?
Mendus AB has 19 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.